Published in:
Open Access 14-11-2023 | Breast Cancer | Editorial
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Published in: Oncology and Therapy | Issue 1/2024
Login to get accessExcerpt
|
Since the U.S. Food and Drug Administration (FDA) approval of trastuzumab deruxtecan (T-DXd) for advanced HER2-low breast cancer, researchers and clinicians have raised an important question of whether HER2-low should be considered as a separate clinical entity with distinct molecular and clinicopathological features, or solely a biomarker for a HER2-directed antibody–drug conjugate.
|
|
If HER2-low is considered as a separate clinical subtype, this may require updating the clinical guidelines on human epidermal growth factor receptor 2 (HER2) scoring and testing in breast cancer along with its therapeutic indication.
|
|
This editorial provides current available data on characteristics of HER2-low breast cancer, and most importantly, addresses the recent timely updates from the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on reporting terminology for HER2-low versus HER2-negative breast cancer.
|